Source-grounded facts extracted from Werewolf Therapeutics, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Werewolf Therapeutics, Inc. reported first quarter ended March 31, 2026 results: net income Net loss was $13.5 million for the first quarter of 2026.
“Net loss was $13.5 million for the first quarter of 2026, compared to $18.1 million for the same period in 2025.”
Werewolf Therapeutics, Inc. reported full year ended December 31, 2025 results: net income Net loss was $60.8 million.
“Net loss was $60.8 million for the full year 2025”
Werewolf Therapeutics, Inc. reported quarter ended December 31, 2025 results: net income Net loss was $8.4 million.
“Net loss was $8.4 million for the fourth quarter of 2025”
Werewolf Therapeutics, Inc. announced a restructuring with charges of approximately $4.1 million (64% of the Company’s workforce).
“estimates that it will record a one-time charge in the first quarter of 2026 related to employee separation benefits, including severance and related benefits, of approximately $4.1 million, all of which is anticipated to result in cash expenditures to be incurred in the first quarter of 2026. The Company may also incur additional costs not currently contemplated”
Werewolf Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A), 5810(c)(3)(H)).
“February 4, 2026, Werewolf Therapeutics, Inc. (the “Company”) received a deficiency letter (the “Notice”) from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market, LLC (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days, the bid price for the Company’s common stock had closed below $1.00 per share, which is the minimum bid price required to maintain continued listing on the Nasdaq Global Select Market under Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Requirement”). The Notice has no immediate effect on the listing of the Company’s co”
Werewolf Therapeutics, Inc. received a nasdaq noncompliance notice notice (rules 5605(c)(2), 5605(c)(4)(B)).
“October 2, 2025, the Company notified Nasdaq of the resulting non-compliance with Nasdaq listing rules caused by Dr. Lazarus’s passing. Pursuant to Nasdaq Listing Rule 5605(c)(4)(B), the Company is entitled to a cure period to regain compliance with Nasdaq Listing Rule 5605(c)(2), which cure period will expire upon the earlier of the Company’s next annual meeting of stockholders or September 30, 2026. The Company also informed Nasdaq that the Board plans to regain compliance with the listing rules at its earliest opportunity by appointing an additional independent director of the Company to fi”
Werewolf Therapeutics, Inc.: Adopted Third Amended and Restated Bylaws to revise stockholder nomination procedures, clarify meeting presiding officers, and make administrative changes (effective 2025-06-12).
“On June 12, 2025, the board of directors of Werewolf Therapeutics, Inc. (the “Company”) adopted amended and restated bylaws of the Company (as amended and restated, the “Third Amended and Restated Bylaws” ), effective immediately, in order to, among other things: (a) revise and clarify certain procedural mechanics and informational requirements in connection with stockholder nominations of directors and submissions of stockholder proposals pursuant to the advance notice provisions of the Third Amended and Restated Bylaws, including by defining certain terms and requiring such stockholder to update such notice, if necessary, so that it remains true and correct closer to the meeting date; (b) specify individuals who may preside over meetings of the Company’s stockholders; and (c) make other administrative, modernizing, clarifying and conforming changes.”
Anil Singhal, Ph.D. was appointed as Director at Werewolf Therapeutics, Inc..
“On February 19, 2025, the Board of the Company, upon recommendation of the Board’s Nominating and Corporate Governance Committee, appointed Anil Singhal, Ph.D., as a director.”
Derek DiRocco, M.D. resigned as Director at Werewolf Therapeutics, Inc..
“On February 19, 2025, Derek DiRocco, M.D., notified Werewolf Therapeutics, Inc. (the “Company”) of his intent to resign from the Board of Directors (the “Board”) of the Company, effective upon the Company’s 2025 annual meeting of stockholders.”
Werewolf Therapeutics, Inc. reported first quarter ended March 31, 2024 results: revenue $0.7 million.
“be sufficient to fund operational expenses and capital expenditure requirements through at least the first quarter of 2026. • Collaboration revenue: Collaboration revenue was $0.7 million for the first quarter of 2024, compared to $4.5 million for the same period in 2023. Collaboration revenue consists of revenue recognized from the Company’s licensing agreement”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.